Antitumor effect of selected daunorubicin derivatives in mice with P 388 leukemia

Antitumor activity of four modified on amino sugar moiety derivatives of daunorubicin was compared with activity of two commercial preparations of the parental drug in tests against P 388 leukemia in mice. Tested analogs appeared to be similarly effective as the reference drugs, but two of them, DR-2 and DR-19, were found to be significantly less potent.